Atrium Therapeutics, Inc.
RNA
$10.51
-$0.84-7.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -84.70% | 2,185.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.70% | 2,185.80% | |||
| Cost of Revenue | -7.89% | 16.58% | |||
| Gross Profit | -514.34% | 122.18% | |||
| SG&A Expenses | -49.26% | 29.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.59% | 23.21% | |||
| Operating Income | -30.89% | 40.62% | |||
| Income Before Tax | -21.36% | 42.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.36% | 42.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.36% | 42.91% | |||
| EBIT | -30.89% | 40.62% | |||
| EBITDA | -30.04% | 40.89% | |||
| EPS Basic | -21.36% | 48.22% | |||
| Normalized Basic EPS | -21.36% | 48.16% | |||
| EPS Diluted | -21.36% | 48.22% | |||
| Normalized Diluted EPS | -21.36% | 48.16% | |||
| Average Basic Shares Outstanding | 0.00% | 10.25% | |||
| Average Diluted Shares Outstanding | 0.00% | 10.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||